Authors: Stypinski, D McQuarrie, SA Wiebe, LI Tam, YK Mercer, JR McEwan, AJB

Citation: D. Stypinski et al., Dosimetry estimations for I-123-IAZA in healthy volunteers, J NUCL MED, 42(9), 2001, pp. 1418-1423

Authors: Donovan, JM Stypinski, D Stiles, MR Olson, TA Burke, SK

Citation: Jm. Donovan et al., Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent, CARDIO DRUG, 14(6), 2000, pp. 681-690

Authors: Kimanani, E Stypinski, D Curtis, G Stiles, M Heessels, P Logan, S Nelson, K St Germain, E Boswell, G

Citation: E. Kimanani et al., A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products, J CLIN PHAR, 40(10), 2000, pp. 1102-1108

Authors: Stypinski, D Wiebe, LI Tam, YK Mercer, JR McEwan, AJB

Citation: D. Stypinski et al., Effects of methoxyflurane anesthesia on the pharmacokinetics of I-125-IAZAin Sprague-Dawley rats, NUCL MED BI, 26(8), 1999, pp. 959-965

Authors: Kumar, P Stypinski, D Xia, H McEwan, AJB Machulla, HJ Wiebe, LI

Citation: P. Kumar et al., Fluoroazomycin arabinoside (FAZA): Synthesis, H-2 and H-3-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia., J LABEL C R, 42(1), 1999, pp. 3-16

Authors: Stypinski, D Wiebe, LI McEwan, AJ Schmidt, RP Tam, YK Mercer, JR

Citation: D. Stypinski et al., Clinical pharmacokinetics of I-123-IAZA in healthy volunteers, NUCL MED C, 20(6), 1999, pp. 559-567